Back to Homepage


Watch the video abstract which outlines the thematic series on the changing face of migraine


Special themed collection: The changing face of migraine
Editors: Messoud Ashina, Lars Edvinsson, Paolo Martelletti Journal of Headache and Pain

Migraine management has long relied on medication developed to treat other conditions. However, the emergence of a new class of preventative drugs is now within our grasp. Targeted prophylactic migraine treatment is becoming a reality and the neuropeptide calcitonin gene-related peptide (CGRP) plays a central role in this breakthrough.

This topical collection explores the changing face of migraine and examines where we are in meeting the long-standing unmet need for a more individualized and targeted approach.

A new article collection on The Changing Face of Migraine is available. Watch the video abstract to know more

Editorial
The changing face of migraine
Paolo Martelletti, Messoud Ashina and Lars Edvinsson

Review articles
Advantages in genetics of migraine
Heidi G. Sutherland, Cassie L. Albury and Lyn R. Griffiths

Optimising migraine treatment: from drug-drug interactions to personalized medicine
Leda Marina Pomes,  Martina Guglielmetti, Enrico Bertamino, Maurizio Simmaco, Marina Borro and Paolo Martelletti

The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse
Willem Sebastiaan van Hoogstraten and Antoinette MaassenVanDenBrink

How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
Cindy Tiseo, Raffaele Ornello, Francesca Pistoia and Simona Sacco

A narrative review on the burden of migraine: when the burden is the impact on people’s life
Matilde Leonardi and Alberto Raggi

Therapeutic novelties in migraine: new drugs, new hope?
Thien Phu Do, Song Guo and Messoud Ashina

Perspective
Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)
Paolo Martelletti, Lars Edvinsson and Messoud Ashina

Funding
This programme is made possible thanks to independent educational sponsorship from Eli Lilly and Company.